重症COVID-19患者的临床脓毒症表型
该研究将既往在非COVID-19脓毒症中识别的四种临床表型应用于52,274例重症患者,包括两个COVID-19脓毒症队列(地塞米松成为标准治疗前后)和三个非COVID-19脓毒症队列(非COVID-19病毒性肺炎脓毒症、细菌性肺炎脓毒症、非肺部来源细菌性脓毒症)。COVID-19与非COVID-19病毒性肺炎脓毒症的表型分布高度相似,而两个细菌性脓毒症队列的δ表型比例高于病毒性脓毒症队列。地塞米松治疗与δ表型比例增加相关(地塞米松前队列6% vs 地塞米松后队列11%,p < 0.001)。各队列中α表型结局最好,δ表型死亡率最高;地塞米松引入后δ表型生存率显著提高(60% vs 41%,p < 0.001),其他表型无相关差异。作者认为对重症COVID-19患者进行临床表型分类可能有助于预后判断、疗效预测和个体化医疗。
要点
- 在52,274例重症患者中,COVID-19脓毒症与非COVID-19病毒性肺炎脓毒症的表型分布高度相似。
- 两个细菌性脓毒症队列的δ表型比例高于病毒性脓毒症队列。
- 地塞米松成为标准治疗后,COVID-19队列δ表型比例由6%升至11%(p < 0.001)。
- 各队列中α表型结局最好,δ表型死亡率最高。
- 地塞米松引入后δ表型生存率由41%升至60%(p < 0.001),其他表型无相关差异。
适用人群与场景
- 共计52,274例重症患者,包括两个COVID-19脓毒症队列(地塞米松成为标准治疗前后)和三个非COVID-19脓毒症队列(非COVID-19病毒性肺炎脓毒症、细菌性肺炎脓毒症、非肺部来源细菌性脓毒症)。
研究设计与关键结果
- 研究类型:将四种非COVID-19脓毒症表型应用于52,274例重症患者,比较各队列间表型比例及表型相关死亡率差异。
- COVID-19脓毒症与非COVID-19病毒性肺炎脓毒症队列的表型分布高度相似。
- 两个细菌性脓毒症队列的δ表型比例高于病毒性脓毒症队列。
- 地塞米松成为标准治疗后,COVID-19队列δ表型比例增加(地塞米松前6% vs 地塞米松后11%,p < 0.001)。
- 各队列中α表型与最佳结局相关,δ表型与最高死亡率相关。
- 地塞米松引入后δ表型生存率明显提高(60% vs 41%,p < 0.001),COVID-19患者其他表型间生存率无相关差异。
证据类型、等级与局限
- 证据类型:基于52,274例重症患者的队列分析(原文未报告证据等级)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,将重症COVID-19患者分类为临床表型可能有助于预后判断、疗效预测和促进个体化医疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A greater understanding of disease heterogeneity may facilitate precision medicine for coronavirus disease 2019 (COVID-19). Previous work identified four distinct clinical phenotypes associated with outcome and treatment responses in non-COVID-19 sepsis patients, but it is unknown if and how these phenotypes are recapitulated in COVID-19 sepsis patients.
METHODS: We applied the four non-COVID-19 sepsis phenotypes to a total of 52,274 critically ill patients, comprising two cohorts of COVID-19 sepsis patients (admitted before and after the introduction of dexamethasone as standard treatment) and three non-COVID-19 sepsis cohorts (non-COVID-19 viral pneumonia sepsis, bacterial pneumonia sepsis, and bacterial sepsis of non-pulmonary origin). Differences in proportions of phenotypes and their associated mortality were determined across these cohorts.
RESULTS: Phenotype distribution was highly similar between COVID-19 and non-COVID-19 viral pneumonia sepsis cohorts, whereas the proportion of patients with the δ-phenotype was greater in both bacterial sepsis cohorts compared to the viral sepsis cohorts. The introduction of dexamethasone treatment was associated with an increased proportion of patients with the δ-phenotype (6% vs. 11% in the pre- and post-dexamethasone COVID-19 cohorts, respectively, p < 0.001). Across the cohorts, the α-phenotype was associated with the most favorable outcome, while the δ-phenotype was associated with the highest mortality. Survival of the δ-phenotype was markedly higher following the introduction of dexamethasone (60% vs 41%, p < 0.001), whereas no relevant differences in survival were observed for the other phenotypes among COVID-19 patients.
CONCLUSIONS: Classification of critically ill COVID-19 patients into clinical phenotypes may aid prognostication, prediction of treatment efficacy, and facilitation of personalized medicine.
参考来源
- Bruse N, Kooistra EJ, Jansen A, et al. Clinical sepsis phenotypes in critically ill COVID-19 patients. Crit Care. 2022. PMID: 35945618. doi:10.1186/s13054-022-04118-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。